Responses
Regular and young investigator award abstracts
Clinical trials completed
268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)
Compose a Response to This Article
Other responses
No responses have been published for this article.
